Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endoscopic Radiofrequency Ablation Combined With Gemcitabine and S-1 in Paitiens for Unresectable Cholangiocarcinoma：A Randomized Open-label Clinical Trial

NCT05028439 is registered in ClinicalTrials.gov with First People's Hospital of Hangzhou as lead sponsor.

NCT NCT05028439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05028439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endoscopic Radiofrequency Ablation Combined With Gemcitabine and S-1 in Paitiens for Unresectable Cholangiocarcinoma：A Randomized Open-label Clinical Trial
Lead sponsor
First People's Hospital of Hangzhou
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2020
Completion date
December 30, 2022
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma